NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Bausch + Lomb BLCO shares ended the last trading session 13.9% higher at $12.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

We have seen 57 institutional investors add shares of $BLCO stock to their portfolio, and 57 decrease their positions in their most recent quarter.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bausch + Lomb (NYSE:BLCO) continued to trade lower on Friday as Wells Fargo downgraded the Canadian eyecare firm in reaction to a voluntary recall of several brands of its enVista line of ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $17.00 ...

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia ...

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. The medical ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the ...